- Home
- XLO vs EDAP Comparison
XLO vs EDAP Comparison
Compare XLO & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XLO
- EDAP
- Stock Information
- Founded
- XLO 2016
- EDAP 1979
- Country
- XLO United States
- EDAP France
- Employees
- XLO N/A
- EDAP N/A
- Industry
- XLO Biotechnology: Pharmaceutical Preparations
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- XLO Health Care
- EDAP Health Care
- Exchange
- XLO Nasdaq
- EDAP Nasdaq
- Market Cap
- XLO 40.9M
- EDAP 46.7M
- IPO Year
- XLO 2021
- EDAP 1997
- Fundamental
- Price
- XLO $0.80
- EDAP $2.14
- Analyst Decision
- XLO Buy
- EDAP Buy
- Analyst Count
- XLO 2
- EDAP 3
- Target Price
- XLO $3.00
- EDAP $8.50
- AVG Volume (30 Days)
- XLO 604.4K
- EDAP 71.5K
- Earning Date
- XLO 11-07-2025
- EDAP 11-06-2025
- Dividend Yield
- XLO N/A
- EDAP N/A
- EPS Growth
- XLO N/A
- EDAP N/A
- EPS
- XLO N/A
- EDAP N/A
- Revenue
- XLO $15,001,000.00
- EDAP $74,008,221.00
- Revenue This Year
- XLO $519.70
- EDAP N/A
- Revenue Next Year
- XLO $44.57
- EDAP N/A
- P/E Ratio
- XLO N/A
- EDAP N/A
- Revenue Growth
- XLO 536.45
- EDAP 1.56
- 52 Week Low
- XLO $0.62
- EDAP $1.21
- 52 Week High
- XLO $1.70
- EDAP $3.05
- Technical
- Relative Strength Index (RSI)
- XLO 52.39
- EDAP 46.50
- Support Level
- XLO $0.73
- EDAP $1.75
- Resistance Level
- XLO $0.90
- EDAP $2.27
- Average True Range (ATR)
- XLO 0.06
- EDAP 0.25
- MACD
- XLO 0.00
- EDAP -0.04
- Stochastic Oscillator
- XLO 41.23
- EDAP 37.50
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.